Logo image of VNDA

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

NASDAQ:VNDA - Nasdaq - US9216591084 - Common Stock - Currency: USD

4.24  -0.08 (-1.85%)

Premarket: 4.34 +0.1 (+2.36%)

Fundamental Rating

3

Overall VNDA gets a fundamental rating of 3 out of 10. We evaluated VNDA against 561 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year VNDA has reported negative net income.
VNDA had a negative operating cash flow in the past year.
VNDA had positive earnings in 4 of the past 5 years.
VNDA had a positive operating cash flow in 4 of the past 5 years.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

The Return On Assets of VNDA (-2.88%) is better than 88.59% of its industry peers.
Looking at the Return On Equity, with a value of -3.51%, VNDA belongs to the top of the industry, outperforming 90.20% of the companies in the same industry.
Industry RankSector Rank
ROA -2.88%
ROE -3.51%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

Looking at the Gross Margin, with a value of 94.31%, VNDA belongs to the top of the industry, outperforming 94.12% of the companies in the same industry.
VNDA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VNDA has more shares outstanding than it did 1 year ago.
VNDA has more shares outstanding than it did 5 years ago.
VNDA has a worse debt/assets ratio than last year.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 1.62, we must say that VNDA is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.62, VNDA is in the better half of the industry, outperforming 72.19% of the companies in the same industry.
VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of VNDA (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 1.62
ROIC/WACCN/A
WACC10.04%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 4.39 indicates that VNDA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 4.39, VNDA is in line with its industry, outperforming 50.27% of the companies in the same industry.
VNDA has a Quick Ratio of 4.37. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
VNDA has a Quick ratio (4.37) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.39
Quick Ratio 4.37
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VNDA have decreased strongly by -837.50% in the last year.
Looking at the last year, VNDA shows a small growth in Revenue. The Revenue has grown by 3.18% in the last year.
The Revenue has been decreasing by -2.64% on average over the past years.
EPS 1Y (TTM)-837.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-614.29%
Revenue 1Y (TTM)3.18%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%5.44%

3.2 Future

The Earnings Per Share is expected to grow by 23.95% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 1.13% on average over the next years.
EPS Next Y-376%
EPS Next 2Y-11.02%
EPS Next 3Y23.95%
EPS Next 5YN/A
Revenue Next Year14.18%
Revenue Next 2Y26.33%
Revenue Next 3Y22.5%
Revenue Next 5Y1.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year VNDA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

A more expensive valuation may be justified as VNDA's earnings are expected to grow with 23.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-11.02%
EPS Next 3Y23.95%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (5/22/2025, 8:00:01 PM)

Premarket: 4.34 +0.1 (+2.36%)

4.24

-0.08 (-1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-07 2025-05-07/amc
Earnings (Next)07-29 2025-07-29
Inst Owners76.83%
Inst Owner Change3.44%
Ins Owners3.07%
Ins Owner Change18.15%
Market Cap249.86M
Analysts80
Price Target12.92 (204.72%)
Short Float %8.47%
Short Ratio7.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.23%
Min EPS beat(2)26.47%
Max EPS beat(2)45.98%
EPS beat(4)3
Avg EPS beat(4)-25.54%
Min EPS beat(4)-237.25%
Max EPS beat(4)62.65%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.58%
Min Revenue beat(2)-4.96%
Max Revenue beat(2)-0.2%
Revenue beat(4)1
Avg Revenue beat(4)-1.46%
Min Revenue beat(4)-4.96%
Max Revenue beat(4)3.39%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)17.26%
PT rev (3m)21.47%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4376.14%
EPS NY rev (1m)-33.33%
EPS NY rev (3m)-834.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-26.04%
Revenue NY rev (1m)2.19%
Revenue NY rev (3m)-20.07%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.26
P/FCF N/A
P/OCF N/A
P/B 0.46
P/tB 0.59
EV/EBITDA N/A
EPS(TTM)-0.75
EYN/A
EPS(NY)-0.39
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.27
OCFYN/A
SpS3.37
BVpS9.14
TBVpS7.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.88%
ROE -3.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.31%
FCFM N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.3
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.03%
Cap/Sales 0.25%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.39
Quick Ratio 4.37
Altman-Z 1.62
F-Score3
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-837.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-614.29%
EPS Next Y-376%
EPS Next 2Y-11.02%
EPS Next 3Y23.95%
EPS Next 5YN/A
Revenue 1Y (TTM)3.18%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%5.44%
Revenue Next Year14.18%
Revenue Next 2Y26.33%
Revenue Next 3Y22.5%
Revenue Next 5Y1.13%
EBIT growth 1Y-191.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-230.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-223.09%
OCF growth 3YN/A
OCF growth 5YN/A